Antiplatelet Drugs Market To Surpass US$ 2.9 Billion By 2026 – Exclusive Report By CoherentMarketInsights™
Overview
People with a serious heart problem are administered antiplatelet medications, which help to prevent heart attacks from happening again. Ticagrelor, clopidogrel, aspirin, and prasugrel are examples of antiplatelet medicines. In the absence of hypersensitivity, aspirin is indicated for all individuals with Acute Coronary Syndrome (ACS). Prasugrel is given to individuals with ACS and those who are having a PCI or Percutaneous Coronary Intervention. Clopidogrel and Ticagrelor are used to prevent atherothrombotic occurrences in elderly patients with ACS who have had a CABG (coronary artery bypass graft).
The global antiplatelet drugs market was worth US$ 1.5 billion in 2017 and is anticipated to grow at a 7.6 percent CAGR from 2018 to 2026.
Drivers
The global antiplatelet drugs market is being driven by an increase in the frequency of cardiovascular diseases, a rising elderly population, and a sedentary lifestyle. In both developed and developing economies, cardiovascular illnesses are the leading cause of mortality. As per the Centers for Disease Control and Prevention (CDC), about 800,000 individuals in the United States die each year from heart attack and other cardiovascular illnesses, according to a data from 2015.
Restraints
Some antiplatelet medications have been ruled out for usage in patients due to effectiveness, safety, and tolerability issues. Antiplatelet medications can cause gastrointestinal side effects such as indigestion and stomach pains by irritating the stomach lining. Since these medications impair the capacity of the blood to clot, individuals using them may be more susceptible to sneezing, bruises, or bleeding for longer periods of time than normal. According to a 2011 research published in the Journal of Clinical Gastroenterology, the gastrointestinal system is the site of most spontaneous bleeding in patients on antiplatelet medicines, with a frequency of 2-3 percent with dual antiplatelet treatment. Furthermore, due to rebound platelet activation, failing to take antiplatelet medications as prescribed could raise the risk of coagulant problems. Over the forecast period, all of these aspects are projected to limit the growth of the global antiplatelet drugs market.
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/2190
Regional Analysis
The global antiplatelet drug market in North America and Europe is anticipated to expand significantly by 2026, as cardiovascular illnesses are the leading cause of mortality in these areas. According to a research published in the European Heart Journal in 2014, Coronary Heart Diseases (CHD), notably Myocardial Infarction (MI), cause around 1.8 million fatalities in Europe each year.
The growth of the global antiplatelet market in Asia Pacific is projected to be fueled by the rising prevalence of cardiovascular disorders in the area. As per the American Heart Association, cardiovascular diseases caused 17,050 deaths among Asian and Pacific Islanders in 2011, with 7,828 deaths attributable to coronary heart disease and 2,476 fatalities owing to myocardial infarction.
People in Asia Pacific, on the other hand, are more sensitive to antithrombotics or fibrinolytics, and are linked to increased risk of complications during the treatment of ischemic heart disease and antithrombotic therapy, according to research published in the American Heart Journal in 2015. Patients in Asia Pacific, particularly in its eastern area, have had increased bleeding risk with normal dosages of novel P2Y12 inhibitors. As per a research published in the Circulation Journal in 2014, a lower maintenance dosage of 3.75 mg daily for Prasugrel was utilized in clinical tests and was authorized for Japanese patients. Patients in Asia Pacific have a lower body weight, most antiplatelet medications have a set dose regimen, and they have distinct genetic origins, all of which might contribute to an increased risk of bleeding. As a result, while choosing antiplatelet medications for patients in Asia Pacific, bleeding is a major issue.
Competitive Landscape
Major companies contributing in the global antiplatelet drugs market are Daiichi Sankyo, Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Sanofi, The Medicines Company, AstraZeneca Plc, Otsuka Pharmaceutical Company, Ltd., Merck & Co., Inc., and Eli Lilly and Company.
Main points in Antiplatelet Drugs Market Report Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Antiplatelet Drugs Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Antiplatelet Drugs Industry Impact
Chapter 2 Global Antiplatelet Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Antiplatelet Drugs (Volume and Value) by Type
2.3 Global Antiplatelet Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Antiplatelet Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Antiplatelet Drugs Market Analysis
Chapter 6 East Asia Antiplatelet Drugs Market Analysis
Chapter 7 Europe Antiplatelet Drugs Market Analysis
Chapter 8 South Asia Antiplatelet Drugs Market Analysis
Chapter 9 Southeast Asia Antiplatelet Drugs Market Analysis
Chapter 10 Middle East Antiplatelet Drugs Market Analysis
Chapter 11 Africa Antiplatelet Drugs Market Analysis
Chapter 12 Oceania Antiplatelet Drugs Market Analysis
Chapter 13 South America Antiplatelet Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Antiplatelet Drugs Business
Chapter 15 Global Antiplatelet Drugs Market Forecast (2021-2027)
Chapter 16 Conclusions
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
